From September 2-3, the National Institute of Food and Drug Safety Evaluation (NIFDS) and the Drug Information Association will host a symposium on regulatory developments, vaccine development, and novel drugs related to Covid-19.
The online workshop will feature representatives from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The Drug Information Association (DIA) is a non-profit organization based in the United States that has members from over 80 countries. It was founded in 1964. To promote global healthcare, it holds conferences, offers regular training courses, and publishes journals on the development and approval of medicinal products.
During the two-day event, NIFDS will host a joint online conference with the two major worldwide regulators to discuss the rapid development of Covid-19 treatments and vaccines, regulatory trends, and innovative drug development strategies.
On the first day, FDA and EMA authorities will discuss how to make Covid-19 medicines and vaccines more accessible, as well as relevant regulations. Domestic pharmaceutical companies would describe their plans for novel medication research and worldwide patent protection the next day, and the FDA would present practical strategies to speed up the process.
The meeting was organized to improve the domestic pharmaceutical and biotechnology industry’s international competitiveness. The ministry gathered regulators as well as domestic and international industry professionals to discuss the development of the Covid-19 treatment vaccine, regulatory trends, and plans for creating novel medications in Korea for export.
Director Peter Marks of the Center for Biologics Evaluation and Research and John Farley of the Office of Infectious Diseases at the FDA, as well as EMA executive Thomas Larsson, will give an overview of worldwide regulatory trends for quick response to Covid-19.
In addition, 17 speakers, including pharmaceutical industry leaders, will discuss the most recent treatments and vaccines, as well as their experiences and strategies for entering worldwide markets.